semaglutide hfpef trial in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction ESC 2025: study supports use

Name: semaglutide hfpef trial in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction ESC 2025: study supports use
Brand: matisco.be
SKU: 63318640004
Price: 26.39 USD
Availability: InStock
Rating: 4.3807 (5 reviews)

SKU: 63318640004

4.4

USD26.39 USD75.39

Pay in 4 interest-free payments of $6.60 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

ESC 2025: study supports use of semaglutide, tirzepatide in cardiometabolic HFpEF patients Clinical Trials Arena Efficacy of Semaglutide by Sex in Obesity Related Heart Failure With Preserved Ejection Fraction: STEP HFpEF Trials JACC Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial The Lancet Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss npj Cardiovascular Health

Store: matisco.be · Domain: matisco.be

Description

Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis